Comprehensive analysis of the clinical immuno-oncology landscape
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Advances from immuno-oncology (IO) are changing the standard of care of many types of cancer, and the paradigm of cancer treatments and drug development is being rewritten on a regular basis. Moreover, an unprecedented number of new investigational agents and companies are entering the field of IO. As such, it has become challenging for oncology physicians conducting clinical trials, industry veterans developing IO drugs, and even regulators reviewing novel IO agents to keep track of the rapidly evolving landscape. To help the key stake holders in the field understand the latest IO landscape, we sought to present an unbiased, neutral, scientifically curated, and timely updated analysis of all the current IO agents in clinical development and the clinical trials testing these agents. We based our analyses on information collected from numerous trusted and publicly available sources. We have developed two databases. One database tracks 2004 IO agents (940 in clinical stage and 1064 in preclinical stage) against 303 targets, from 864 companies; the other tracks 3042 active clinical trials of these agents with a target enrollment of 577 076 patients. This report provides key analyses of these data. Furthermore, we will discuss a number of important and actionable trends in the current IO landscape: a large number of companies developing agents against the same IO targets; a rapid increase in the number of anti-PD-1/L1 combination studies, many of which are testing the same combin…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Several other agents have been approved since then, but a transformation in the landscape of IO started with the approval of ipilimumab—a checkpoint inhibitor targeting CTLA4—for advanced melanoma in 2011 [2, 3].”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 1×
“It was known that tumors with high level of microsatellite instability (MSI-H) or deficiency in mismatch DNA repair (dMMR) have very high level of nonsynonymous mutations and high immunogenicity, which associates with a high response rate to anti-PD-1 therapy [20, 21].”
BackgroundPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 3×
“This could possibly be driven by the evidence of preclinical synergy of the combination [13], or the recent approvals of antiPD-1/anti-CTLA-4 combination for advanced melanoma and anti-PD-1/chemotherapy combination as the first-line treatment of advanced non-small-cell lung cancer (NSCLC) [14, 15].”
ResultElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“com/pages/map), which evolved from a recent landmark review paper, serves as a centralized information hub for new IO targets and factors that affect tumor immunology [28].”
BackgroundDurvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774 · cited 1×
“In <4 years, KEYNOTE-001 went from IND filing to the approval of pembrolizumab for ipilimumab-resistant metastatic melanoma [18].”
BackgroundLanger, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023 · cited 1×
“This confirms our assumption of significant duplication, despite the fact that five anti-PD-1/L1 monoclonal antibodies have already been approved [9].”
BackgroundMaster Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Woodcock, J., & LaVange, L. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510062 · Cited by 1,020
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 766
Talpaz, M., Kantarjian, H. M., McCredie, K., Trujillo, J. M., Keating, M. J., & Gutterman, J. U. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604243141701 · Cited by 647
Locke, F. L., Neelapu, S. S., Bartlett, N. L., Siddiqi, T., Chavez, J. C., Hosing, C. M., Ghobadi, A., Budde, L. E., Bot, A., Rossi, J. M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.020 · Cited by 620
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Emens, L. A., Ascierto, P. A., Darcy, P. K., Demaria, S., Eggermont, A. M. M., Redmond, W. L., Seliger, B., & Marincola, F. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.035 · Cited by 566
Herbst, R. S., Gandara, D. R., Hirsch, F. R., Redman, M. W., LeBlanc, M., Mack, P. C., Schwartz, L. H., Vokes, E., Ramalingam, S. S., Bradley, J. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3473 · Cited by 244
Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
Johnson, J. R., Ning, Y.-M., Farrell, A., Justice, R., Keegan, P., & Pazdur, R. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr062 · Cited by 212
Melanoma drug wins US approval
Ledford, H. (2011) · Nature · doi:10.1038/471561a · Cited by 163
Kang, S. P., Gergich, K., Lubiniecki, G. M., de Alwis, D. P., Chen, C., Tice, M. A. B., & Rubin, E. H. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx076 · Cited by 110
Accelerated Approval of Oncology Products: A Decade of Experience
Dagher, R. N., Johnson, J. R., Williams, G., Keegan, P., & Pazdur, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh279 · Cited by 91
First-Ever CAR T-cell Therapy Approved in U.S.
(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2017-126 · Cited by 79
Landmark approval for Dendreon's cancer vaccine
DeFrancesco, L. (2010) · Nature Biotechnology · doi:10.1038/nbt0610-531 · Cited by 44
CAR-T Cell Therapy: From the Bench to the Bedside
Golubovskaya, V. (2017) · Cancers · doi:10.3390/cancers9110150 · Cited by 30
Finding fault with Bial's fatal FAAH inhibitor
Mullard, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.129 · Cited by 6
Genetic biomarker trumps tissue type in landmark oncology approval
Mullard, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.128 · Cited by 2
Cited by
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
“Regulation of Immunomodulators IMs are critical for cancer immunotherapy with numerous IM agonists and antagonists being evaluated in clinical oncology (Tang et al., 2018).”
BackgroundFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Metadata
- Authors
- Tang, J., Shalabi, A., & Hubbard-Lucey, V. M.
- Affiliations
- Cancer Research Institute (US)
- Corresponding author
- Hubbard-Lucey, V.M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 29
- Issue
- 1
- Pages
- 84-91
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2774533844
- Cited by
- 508
- References
- 29
- Citations by year
- 2026: 12 · 2025: 35 · 2024: 30 · 2023: 40 · 2022: 57 · 2021: 87 · 2020: 99 · 2019: 88 · 2018: 56
- FWCI
- 29.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 722 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, clinical trials, investigator-initiated trials, anticancer drug development, research duplication, clinical trial recruitment
- MeSH terms
- Antineoplastic Agents, Immunological, Clinical Trials as Topic, Humans, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.